ECSP077351A - PRODUCCIÓN DE a-BETA - Google Patents
PRODUCCIÓN DE a-BETAInfo
- Publication number
- ECSP077351A ECSP077351A EC2007007351A ECSP077351A ECSP077351A EC SP077351 A ECSP077351 A EC SP077351A EC 2007007351 A EC2007007351 A EC 2007007351A EC SP077351 A ECSP077351 A EC SP077351A EC SP077351 A ECSP077351 A EC SP077351A
- Authority
- EC
- Ecuador
- Prior art keywords
- accumulated
- culture
- amino acids
- molar ratio
- glutamine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/04—Plant cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se provee un sistema mejorado para la producción a gran escala de proteínas y a-Beta en cultivo de células, en particular, en medios caracterizados por una o más de las siguientes características: 1) una concentración acumulada de aminoácidos mayor que aproximadamente 70 mM; 2) una relación molar de glutamina acumulada a asparagina acumulada inferior a aproximadamente 2; 3) una relación molar de glutamina acumulada a aminoácidos totales acumulados inferior a aproximadamente 0,2; 4) una relación molar de ion inorgánico acumulado a aminoácidos totales acumulados de entre alrededor de 0,4 y 1; o 5) una concentración combinada de glutamina acumulada y asparagina acumulada de entre aproximadamente 16 y 36 mM. El uso de dicho sistema permite altos niveles de producción de a-Beta, y disminuye la acumulación de ciertos factores indeseables, tales como amonio y lactato. Adicionalmente, se proveen métodos de cultivo que incluyen un cambio de temperatura, que habitualmente comprende una disminución en la temperatura cuando el cultivo ha alcanzado alrededor de 20%-80% de su densidad celular máxima. Alternativa o adicionalmente, la presente invención provee métodos tales que, después de alcanzar un pico, los niveles de lactato y amonio en el cultivo disminuyen con el transcurso del tiempo
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60493604P | 2004-08-27 | 2004-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP077351A true ECSP077351A (es) | 2008-03-26 |
Family
ID=35500647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2007007351A ECSP077351A (es) | 2004-08-27 | 2007-03-27 | PRODUCCIÓN DE a-BETA |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7335491B2 (es) |
| EP (2) | EP1781803B1 (es) |
| JP (3) | JP2008511328A (es) |
| KR (1) | KR100998857B1 (es) |
| CN (1) | CN101048512B (es) |
| AR (1) | AR050471A1 (es) |
| AU (1) | AU2005280090A1 (es) |
| BR (1) | BRPI0514680A (es) |
| CA (1) | CA2578137C (es) |
| CR (1) | CR8996A (es) |
| EC (1) | ECSP077351A (es) |
| EG (1) | EG25848A (es) |
| ES (1) | ES2599103T3 (es) |
| HN (1) | HN2005000486A (es) |
| IL (1) | IL181587A (es) |
| MX (1) | MX2007002382A (es) |
| MY (1) | MY146097A (es) |
| NO (1) | NO20071571L (es) |
| NZ (1) | NZ591233A (es) |
| PE (2) | PE20060715A1 (es) |
| RU (1) | RU2418858C2 (es) |
| SG (1) | SG155250A1 (es) |
| SV (1) | SV2006002212A (es) |
| TW (1) | TWI374935B (es) |
| UA (1) | UA89644C2 (es) |
| WO (1) | WO2006026408A2 (es) |
| ZA (1) | ZA200702487B (es) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US7335491B2 (en) | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
| TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
| TWI364458B (en) | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
| AR058140A1 (es) * | 2005-10-24 | 2008-01-23 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
| US20070231895A1 (en) * | 2005-11-02 | 2007-10-04 | Lee Gene W | Methods for adapting mammalian cells |
| US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
| HRP20140240T4 (hr) | 2005-11-30 | 2017-02-24 | Abbvie Inc. | Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba |
| EP1959996A2 (en) * | 2005-12-12 | 2008-08-27 | AC Immune S.A. | Monoclonal antibody |
| EP3255141B1 (en) * | 2006-07-13 | 2021-12-01 | Wyeth LLC | Production of antibodies with improved glycosylation pattern |
| EP2046833B9 (en) * | 2006-07-14 | 2014-02-19 | AC Immune S.A. | Humanized antibody against amyloid beta |
| ES2541546T3 (es) * | 2006-11-03 | 2015-07-21 | Wyeth Llc | Sustancias que inhiben la glucólisis en cultivo celular |
| SI2078071T1 (sl) | 2006-11-08 | 2015-05-29 | Wyeth Llc | Racionalno zasnovana gojišča za celično kulturo |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US8895004B2 (en) * | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
| JP5930573B2 (ja) | 2007-03-01 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤の新規使用 |
| AU2008223133A1 (en) * | 2007-03-02 | 2008-09-12 | Wyeth | Use of copper and glutamate in cell culture for production of polypeptides |
| EP2142514B1 (en) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
| TW200902708A (en) * | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
| WO2008136398A1 (ja) | 2007-04-26 | 2008-11-13 | Chugai Seiyaku Kabushiki Kaisha | 高濃度アミノ酸含有培地を用いた細胞の培養方法 |
| ES2529174T3 (es) * | 2007-06-12 | 2015-02-17 | Ac Immune S.A. | Anticuerpos humanizados para amiloide beta |
| US8048420B2 (en) * | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| AU2008311367B2 (en) * | 2007-10-05 | 2014-11-13 | Ac Immune S.A. | Use of anti-amyloid beta antibody in ocular diseases |
| US8039231B2 (en) * | 2008-04-17 | 2011-10-18 | Wyeth Llc | Methods for enhanced production of bone morphogenetic proteins |
| AU2009290563A1 (en) | 2008-09-15 | 2010-03-18 | Genentech, Inc. | Compositions and methods for regulating cell osmolarity |
| HRP20200768T4 (hr) | 2009-08-11 | 2025-03-28 | F. Hoffmann - La Roche Ag | Proizvodnja proteina u mediju za uzgoj stanica bez glutamina |
| JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
| US8470552B2 (en) * | 2009-10-12 | 2013-06-25 | Keck Graduate Institute | Strategy to reduce lactic acid production and control PH in animal cell culture |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| NZ602312A (en) | 2010-03-10 | 2014-02-28 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| RU2563353C2 (ru) | 2010-04-26 | 2015-09-20 | Новартис Аг | Улучшенная среда для культивирования клеток |
| CA2797356C (en) | 2010-04-26 | 2020-12-29 | Novartis Ag | Improved cell culture medium |
| PL2563906T3 (pl) | 2010-04-26 | 2018-04-30 | Novartis Ag | Sposób hodowli komórek cho |
| EP2598882B1 (en) | 2010-07-30 | 2017-07-26 | AC Immune S.A. | Safe and functional humanized antibodies for use in treating an amyloidosis |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| JP2013535981A (ja) | 2010-08-20 | 2013-09-19 | ワイス・エルエルシー | 成長因子不含適合細胞の細胞培養 |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| PT2837680T (pt) * | 2011-07-01 | 2020-04-17 | Amgen Inc | Cultura celular de mamífero |
| FI20115704A7 (fi) | 2011-07-01 | 2013-01-02 | Teknologian Tutkimuskeskus Vtt Oy | Vierasproteiinien tuoton parantaminen |
| US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| US11390663B2 (en) | 2013-10-11 | 2022-07-19 | Regeneron Pharmaceuticals, Inc. | Metabolically optimized cell culture |
| KR102243980B1 (ko) | 2013-10-11 | 2021-04-26 | 리제너론 파마슈티칼스 인코포레이티드 | 대사적으로 최적화된 세포 배양 |
| DE102017203908B3 (de) * | 2017-03-09 | 2018-05-30 | Evonik Technochemie Gmbh | Kulturmedium, umfassend Oligopeptide |
| GB201708655D0 (en) | 2017-05-31 | 2017-07-12 | Ucb Biopharma Sprl | Cell culture methods |
| US20200199528A1 (en) * | 2017-06-16 | 2020-06-25 | Katholieke Universiteit Leuven | Cell culture media for differentiation of stem cells into hepatocytes |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| HRP20240584T1 (hr) * | 2018-07-03 | 2024-07-19 | Bristol-Myers Squibb Company | Postupak proizvodnje rekombinantnih proteina |
| SG11202110968VA (en) | 2019-12-06 | 2021-10-28 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
| KR20220143108A (ko) * | 2020-02-18 | 2022-10-24 | 베링거 인겔하임 인터내셔날 게엠베하 | 포유 동물 세포 배양 공정 |
| KR20230039734A (ko) | 2020-07-23 | 2023-03-21 | 오타이르 프로테나 리미티드 | 항-Aβ 항체 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5672502A (en) | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
| GB8516415D0 (en) * | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| ATE135397T1 (de) * | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| US6291159B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
| US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
| US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
| NZ235148A (en) | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
| JPH0396383A (ja) | 1989-09-08 | 1991-04-22 | Riso Kagaku Corp | 画像形成装置 |
| EP0939121B2 (de) | 1989-09-12 | 2007-12-26 | AHP Manufacturing B.V. | TFN-bindende Proteine |
| AU638762B2 (en) | 1989-10-05 | 1993-07-08 | Optein Inc | Cell-free synthesis and isolation of novel genes and polypeptides |
| US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5538983A (en) * | 1990-05-16 | 1996-07-23 | The Rockefeller University | Method of treating amyloidosis by modulation of calcium |
| US5156964A (en) | 1990-08-16 | 1992-10-20 | Cetus Corporation | Methods for adapting cells for increased product production through exposure to ammonia |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| GB9021679D0 (en) | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
| GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
| GB2251249B (en) | 1990-12-28 | 1995-06-21 | Mogam Biotech Res Inst | High-density medium for animal cell culture |
| JPH059735A (ja) * | 1991-07-09 | 1993-01-19 | Kobe Steel Ltd | ダイヤモンドの気相合成方法 |
| GB9118664D0 (en) * | 1991-08-30 | 1991-10-16 | Celltech Ltd | Cell culture |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| JP3504963B2 (ja) | 1993-10-22 | 2004-03-08 | 智靖 羅 | 抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片 |
| US6310185B1 (en) | 1994-03-08 | 2001-10-30 | Memorial Sloan Kettering Cancer Center | Recombinant human anti-Lewis Y antibodies |
| US5856179A (en) | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
| US5589154A (en) | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
| US5721121A (en) | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
| US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
| JP4306813B2 (ja) | 1995-09-19 | 2009-08-05 | アスビオファーマ株式会社 | 動物細胞の新規培養方法 |
| EP0910413A2 (en) * | 1996-05-08 | 1999-04-28 | F. Hoffmann-La Roche Ag | TREATMENT OF ASTHMA WITH TNFR-Ig |
| WO1998041611A1 (en) * | 1997-03-20 | 1998-09-24 | Regents Of The University Of Minnesota | Process for the continuous culture of cells |
| US20020012991A1 (en) * | 1997-04-07 | 2002-01-31 | Florence Chua Nee Ho Kit Fong | Cell culture media for enhanced protein production |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6537782B1 (en) * | 1998-06-01 | 2003-03-25 | Chugai Seiyaku Kabushiki Kaisha | Media for culturing animal cells and process for producing protein by using the same |
| WO2000023082A1 (en) | 1998-10-19 | 2000-04-27 | Yeda Research And Development Co. Ltd. | Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| EP1385544B1 (en) | 2001-04-30 | 2008-09-24 | Eli Lilly And Company | Humanized antibodies |
| EP2165714B1 (en) | 2001-04-30 | 2013-10-23 | Eli Lilly And Company | Humanized antibodies recognizing the beta-amyloid peptide |
| AU2002316230A1 (en) | 2001-06-13 | 2002-12-23 | Genentech, Inc. | Methods of culturing animal cells and polypeptide production in animal cells |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| EP1572909A4 (en) | 2002-02-21 | 2007-06-06 | Wyeth Corp | PROTEIN CONTAINING A DOMAINE OF FOLLISTATIN |
| BR0307871A (pt) | 2002-02-21 | 2005-04-12 | Wyeth Corp | Proteìnas contendo domìnio de folistatina |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| SG187991A1 (en) | 2002-05-02 | 2013-03-28 | Wyeth Corp | Calicheamicin derivative-carrier conjugates |
| AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| US7335491B2 (en) | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
| TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
| TWI364458B (en) | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
-
2005
- 2005-08-25 US US11/213,317 patent/US7335491B2/en not_active Expired - Fee Related
- 2005-08-25 TW TW094129074A patent/TWI374935B/zh not_active IP Right Cessation
- 2005-08-26 AU AU2005280090A patent/AU2005280090A1/en not_active Abandoned
- 2005-08-26 KR KR1020077004809A patent/KR100998857B1/ko not_active Expired - Fee Related
- 2005-08-26 JP JP2007530148A patent/JP2008511328A/ja active Pending
- 2005-08-26 CN CN2005800368972A patent/CN101048512B/zh not_active Expired - Fee Related
- 2005-08-26 EP EP05791655.3A patent/EP1781803B1/en not_active Expired - Lifetime
- 2005-08-26 AR ARP050103595A patent/AR050471A1/es not_active Application Discontinuation
- 2005-08-26 MY MYPI20054022A patent/MY146097A/en unknown
- 2005-08-26 WO PCT/US2005/030364 patent/WO2006026408A2/en not_active Ceased
- 2005-08-26 CA CA2578137A patent/CA2578137C/en not_active Expired - Fee Related
- 2005-08-26 SV SV2005002212A patent/SV2006002212A/es unknown
- 2005-08-26 PE PE2005000986A patent/PE20060715A1/es not_active Application Discontinuation
- 2005-08-26 HN HN2005000486A patent/HN2005000486A/es unknown
- 2005-08-26 RU RU2007108718/10A patent/RU2418858C2/ru not_active IP Right Cessation
- 2005-08-26 UA UAA200703284A patent/UA89644C2/ru unknown
- 2005-08-26 PE PE2009001268A patent/PE20100147A1/es not_active Application Discontinuation
- 2005-08-26 ES ES05791655.3T patent/ES2599103T3/es not_active Expired - Lifetime
- 2005-08-26 SG SG200905720-9A patent/SG155250A1/en unknown
- 2005-08-26 NZ NZ591233A patent/NZ591233A/xx not_active IP Right Cessation
- 2005-08-26 EP EP10184494A patent/EP2348126A3/en not_active Withdrawn
- 2005-08-26 BR BRPI0514680-1A patent/BRPI0514680A/pt not_active Application Discontinuation
- 2005-08-26 MX MX2007002382A patent/MX2007002382A/es active IP Right Grant
-
2007
- 2007-02-27 EG EGNA2007000224 patent/EG25848A/xx active
- 2007-02-27 IL IL181587A patent/IL181587A/en not_active IP Right Cessation
- 2007-03-16 CR CR8996A patent/CR8996A/es unknown
- 2007-03-26 ZA ZA2007/02487A patent/ZA200702487B/en unknown
- 2007-03-26 NO NO20071571A patent/NO20071571L/no not_active Application Discontinuation
- 2007-03-27 EC EC2007007351A patent/ECSP077351A/es unknown
-
2012
- 2012-02-17 JP JP2012033105A patent/JP2012095671A/ja active Pending
-
2015
- 2015-04-01 JP JP2015075425A patent/JP2015133980A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP077353A (es) | Producción de polipéptidos | |
| ECSP077351A (es) | PRODUCCIÓN DE a-BETA | |
| ECSP077354A (es) | PRODUCCIÓN DE TNFR-Ig | |
| MX2022004102A (es) | Composiciones de oligonucleotidos y metodos de uso de las mismas. | |
| MX2019015525A (es) | Modificacion genetica de ratas. | |
| AR076863A1 (es) | Aparato y metodo para reduccion de materia prima solida. | |
| ES2570382T3 (es) | Composiciones y métodos para la producción de azúcares fermentables | |
| CO6501191A2 (es) | Medio de cultivo celular para expresión de la proteina adamts | |
| CL2018002140A1 (es) | Métodos y composiciones para aumentar la eficiencia de modificación genética dirigida usando reparación genética mediada por oligonucleótidos | |
| AR105602A1 (es) | Medio de cultivo celular suplementado con taurina y métodos de utilización | |
| ES2676600T3 (es) | Fabricación y uso de ARN monocatenario sintetizado in vitro para la introducción en células de mamífero para inducir un efecto biológico o bioquímico | |
| AR051304A1 (es) | Proceso para preparar 4,5-dihidro-pirazolo (3,4) pirid-2-onas e intermediarios | |
| CR9897A (es) | Metodo de produccion proteica utilizando carnosina | |
| EA202090067A2 (ru) | Способ получения рекомбинантного adamts13 в культуре клеток | |
| AR091482A1 (es) | Celulas modificadas geneticamente y metodos par su obtencion | |
| MX2012013037A (es) | Composiciones de endorribonucleasa y metodos de uso de las mismas. | |
| AR090822A1 (es) | Composiciones de cultivo de celulas y metodos para la produccion de polipeptidos | |
| PA8779101A1 (es) | "compuestos tricíclicos como inhibidores de metaloproteinasas matriciales" | |
| MX2018001324A (es) | Forma cristalina de base libre de lorlatinib. | |
| BRPI0912164A2 (pt) | processo para a degradação de lignina. | |
| GT200500330A (es) | Derivados de quinolina e isoquinolina 5-sustituidos, un prodecimiento para su preparacion y su uso como inhibidores de la inflamacion | |
| WO2009155041A3 (en) | Method to modulate hematopoietic stem cell growth | |
| BR112015013071A8 (pt) | solução de trombina aquosa, seus métodos para liofilização e composição de trombina sólida | |
| BR112012026349A2 (pt) | novos métodos para isolar células trl | |
| AR065847A1 (es) | Composicion portadora de rapida accion para la insercion de acido nucleico. metodo. uso. |